Tag: Platinum-Resistant
Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer
July 20, 2022 12:09 pmby Caroline Seymour
The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the … Read more
Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer
June 21, 2022 11:03 amby Chris Ryan
The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.
The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in
Biomarkers May Identify Ovarian Cancer Patients Who Benefit From AstraZeneca WEE1 Inhibitor
June 5, 2022 9:55 amby Caroline Hopkins
CHICAGO – AstraZeneca’s investigational WEE1 inhibitor adavosertib showed potential in biomarker-selected advanced ovarian cancer populations in two studies presented during the American Society of Clinical Oncology’s annual meeting Saturday.
The drug, which AstraZeneca licensed from Merck in … Read more
Navicixizumab Plus Paclitaxel in Platinum-Resistant Ovarian Cancer
April 27, 2022 12:40 pmby Matthew Stenger
In a phase Ib study reported in the Journal of Clinical Oncology, Fu et al found that the combination of navicixizumab (a bispecific antiangiogenic antibody to VEGF and delta-like ligand 4) and paclitaxel showed activity in … Read more
Relacorilant/Nab-Paclitaxel Combo Improves OS in Recurrent, Platinum-Resistant Ovarian Cancer
April 5, 2022 11:17 amby Kristi Rosa
The addition of relacorilant to nab-paclitaxel improved overall survival compared with nab-paclitaxel alone in patients with recurrent, platinum-resistant ovarian cancer.
The addition of relacorilant to nab-paclitaxel (Abraxane) improved overall survival (OS) compared with nab-paclitaxel alone in patients
SORAYA Trial: Antibody-Drug Conjugate Produces Remissions in One-Third of Patients With Drug-Resistant Ovarian Cancer
March 22, 2022 10:22 amby the ASCO Post Staff
In a clinical trial involving patients with ovarian cancer previously treated with platinum-based chemotherapy, a novel antibody-drug conjugate therapy produced a substantially better response than standard treatments, investigators from Dana-Farber Cancer Institute reported at the … Read more
Nemvaleukin Alfa Plus Pembrolizumab Demonstrates Promising Responses, Disease Control in Platinum-Resistant Ovarian Cancer
March 20, 2022 9:55 amby Hayley Virgil
Patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy may experience promising responses and disease control following treatment with nemvaleukin alfa and pembrolizumab.
Treatment with nemvaleukin alfa (ALKS 4230) plus pembrolizumab (Keytruda) yielded tumor responses
New Drug Combination Shown Effective for Patients With Advanced Ovarian Cancer
February 14, 2022 10:17 amby Anne Doerr
A new study led by researchers at Yale Cancer Center and the University of Maryland Greenebaum Comprehensive Cancer Center shows ixabepilone plus bevacizumab (IXA+BEV) is a well-tolerated, effective combination for treatment of platinum/taxane-resistant ovarian cancer compared to … Read more
STRO-002 Produces Deep Responses in Heavily Pretreated Advanced Ovarian Cancer
January 7, 2022 11:18 amby Kristi Rosa
The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.
The FolRα-targeted antibody-drug conjugate (ADC) STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced
Mirvetuximab Elicits Responses in More Than 31% of Patients With FRalpha-High Platinum-Resistant Ovarian Cancer
November 30, 2021 12:10 pmby Nichole Tucker
Top-line results from the phase 3 SORAYA study show promise for mirvetuximab in patients with FRα-high platinum-resistant ovarian cancer.
Single-agent mirvetuximab soravtansine (mirvetuximab; IMGN853) has demonstrated clinically meaningful benefit in patients with late receptor alpha (FRα)-high platinum-resistant
Biomarkers Found for Platinum Resistance in Gynecologic Cancer
November 19, 2021 11:56 amBlood-based metabolic signatures may predict whether women with ovarian or uterine cancer will respond well to platinum-based chemotherapy, according to a study by researchers in the Department of Gynecology at the Federal University of São Paulo’s Medical School (EPM-UNIFESP) in … Read more
Addition of Bevacizumab to Pembrolizumab Improves Responses in Epithelial Ovarian Cancer
November 17, 2021 10:25 amBy Courtney Marabella
The addition of a short-term, flat dose of bevacizumab to pembrolizumab was found to enhance the response to anti–PD-1 therapy in the absence of chemotherapy for patients with platinum-resistant epithelial ovarian cancer.
The addition of a short-term,
Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer
September 30, 2021 2:05 amBy The ASCO Post Staff
For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely … Read more
Intermittent Relacorilant Combined with Nab-paclitaxel Improves PFS in Recurrent Platinum-Resistant Ovarian Cancer
September 17, 2021 4:47 pmIn the first randomised, controlled study to explore the efficacy and safety of relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel compared to nab-paclitaxel alone, combined treatment improved progression-free survival (PFS) and showed a favourable safety profile among … Read more
Tislelizumab Plus Sitravatinib Demonstrates Antitumor Activity, Maintains Safety in Platinum-Resistant Epithelial Ovarian Cancer
April 14, 2021 3:00 pmFor patients with recurrent platinum-resistant epithelial ovarian cancer who were naïve to PD-1/PD-L1 inhibition, the combination treatment of tislelizumab plus sitravatinib showed early antitumor activity while maintaining a manageable safety profile.
By Kristi Rosa
For patients with recurrent platinum-resistant epithelial
Combo Tx Active in Recurrent, Platinum-Resistant Ovarian Cancer
March 26, 2021 1:00 pmIxabepilone plus bevacizumab yielded responses in a third of patients.
By Ian Ingram
Combination treatment with a microtubule stabilizing agent plus bevacizumab (Avastin) proved active for patients with recurrent chemotherapy-resistant ovarian cancer, a randomized phase II trial found.
Median progression-free … Read more
Small Molecule Inhibitor Shows Promise in Resistant Ovarian Cancer
March 21, 2021 5:00 pmResponses in 37% of patients with AVB-500, higher without prior bevacizumab.
By Charles Bankhead
More than a third of patients with platinum-resistant ovarian cancer had objective responses to chemotherapy plus a small-molecule inhibitor that targets resistance-associated signaling, a preliminary study … Read more
Phase 3 OVAL Trial of VB-111 in Platinum-Resistant Ovarian Cancer Gets Green Light to Continue
February 24, 2021 6:00 pmAn independent data safety monitoring committee has not observed any safety issues with the phase 3 OVAL trial examining VB-111 in patients with platinum-resistant ovarian cancer, and as such, has recommended that the trial continue as planned.
By Courtney Marabella… Read more
Wee1 Inhibitor Gets Win in Tough-to-Treat Ovarian Cancer
January 25, 2021 5:00 pmBy Ian Ingram
Adding the Wee1 inhibitor adavosertib to gemcitabine reduced the risk of disease progression and death in women with recurrent, platinum-resistant or -refractory ovarian cancer, a randomized phase II trial showed.
For the primary endpoint of progression-free survival … Read more